JPS57192435A - Modified polypeptide - Google Patents
Modified polypeptideInfo
- Publication number
- JPS57192435A JPS57192435A JP56077153A JP7715381A JPS57192435A JP S57192435 A JPS57192435 A JP S57192435A JP 56077153 A JP56077153 A JP 56077153A JP 7715381 A JP7715381 A JP 7715381A JP S57192435 A JPS57192435 A JP S57192435A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- group
- arom
- physiological activity
- modified polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
PURPOSE: To provide a chemically, modified polypeptide in which antigenicity is eliminated while retaining the physiological activity of polypeptide at a high level, by subjecting amino groups in the molecule of polypeptide with a group contg. a specified polyethylene glycol residue.
CONSTITUTION: Part or the whle of amino groups in the molecule of polypeptide such as uricase, arginase or insulin is substituted with a group of formulaI (wherein R1 is F, Cl, OH or a group which does not react with the polypeptide; the group of formula II is a polyethylene glycol residue having a number- average MW of 5,000W15,000; R2 is alkyl, an arom. group, alkylcarbonyl, arom. carbonyl, alkylaminocarbonyl, arom. amino carbonyl) to produce a modified polypeptide which is an enzyme having a physiological activity effective in the treatment of patients and in which antigenicity is lowered or completely eliminated while retaining highly the physiological activity of the polypeptide.
COPYRIGHT: (C)1982,JPO&Japio
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56077153A JPS57192435A (en) | 1981-05-20 | 1981-05-20 | Modified polypeptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56077153A JPS57192435A (en) | 1981-05-20 | 1981-05-20 | Modified polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS57192435A true JPS57192435A (en) | 1982-11-26 |
Family
ID=13625838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56077153A Pending JPS57192435A (en) | 1981-05-20 | 1981-05-20 | Modified polypeptide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57192435A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59204130A (en) * | 1983-04-30 | 1984-11-19 | Nippon Chemiphar Co Ltd | Oral administration drug containing novel plasminogen activator derivative |
WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
JPH01316400A (en) * | 1988-03-31 | 1989-12-21 | Kyowa Hakko Kogyo Co Ltd | Modified polypeptide |
WO1990006952A1 (en) * | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
JPH04217693A (en) * | 1990-10-23 | 1992-08-07 | Fuji Photo Film Co Ltd | Peptide-containing polyethylene glycol derivative and its use |
US6166183A (en) * | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
WO2002043772A3 (en) * | 2000-11-30 | 2003-07-31 | Shearwater Corp | Water-soluble polymer conjugates of triazine derivatives |
US6956027B2 (en) | 1994-10-12 | 2005-10-18 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US7090835B2 (en) | 1994-10-12 | 2006-08-15 | Amgen, Inc. | N-terminally chemically modified protein compositions and methods |
US7927589B2 (en) | 1998-08-06 | 2011-04-19 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
CZ303751B6 (en) * | 1998-08-06 | 2013-04-24 | Mountain View Pharmaceuticals, Inc. | Uricase pharmaceutical composition, medicament, use and process for preparing thereof |
US8921064B2 (en) | 1998-08-06 | 2014-12-30 | Mountain View Pharmaceuticals, Inc. | Method for purifying urate oxidase tetramers and octamers |
US9926538B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54119082A (en) * | 1978-03-08 | 1979-09-14 | Mihama Hisaharu | Modified asparagenase deactivated antibody property thereof and production |
JPS5599189A (en) * | 1979-01-22 | 1980-07-28 | Mihama Hisaharu | Modified uricase free from antigenicity and its preparation |
-
1981
- 1981-05-20 JP JP56077153A patent/JPS57192435A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54119082A (en) * | 1978-03-08 | 1979-09-14 | Mihama Hisaharu | Modified asparagenase deactivated antibody property thereof and production |
JPS5599189A (en) * | 1979-01-22 | 1980-07-28 | Mihama Hisaharu | Modified uricase free from antigenicity and its preparation |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59204130A (en) * | 1983-04-30 | 1984-11-19 | Nippon Chemiphar Co Ltd | Oral administration drug containing novel plasminogen activator derivative |
WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
JPH01316400A (en) * | 1988-03-31 | 1989-12-21 | Kyowa Hakko Kogyo Co Ltd | Modified polypeptide |
WO1990006952A1 (en) * | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5824778A (en) * | 1988-12-22 | 1998-10-20 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
JPH04217693A (en) * | 1990-10-23 | 1992-08-07 | Fuji Photo Film Co Ltd | Peptide-containing polyethylene glycol derivative and its use |
US6166183A (en) * | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
US6956027B2 (en) | 1994-10-12 | 2005-10-18 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US7090835B2 (en) | 1994-10-12 | 2006-08-15 | Amgen, Inc. | N-terminally chemically modified protein compositions and methods |
US7662933B2 (en) | 1994-10-12 | 2010-02-16 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US8258262B2 (en) | 1994-10-12 | 2012-09-04 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US9885024B2 (en) | 1998-08-06 | 2018-02-06 | Duke University | PEG-urate oxidase conjugates and use thereof |
US7927589B2 (en) | 1998-08-06 | 2011-04-19 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
US8067553B2 (en) | 1998-08-06 | 2011-11-29 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
CZ303751B6 (en) * | 1998-08-06 | 2013-04-24 | Mountain View Pharmaceuticals, Inc. | Uricase pharmaceutical composition, medicament, use and process for preparing thereof |
US8618267B2 (en) | 1998-08-06 | 2013-12-31 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
US8921064B2 (en) | 1998-08-06 | 2014-12-30 | Mountain View Pharmaceuticals, Inc. | Method for purifying urate oxidase tetramers and octamers |
WO2002043772A3 (en) * | 2000-11-30 | 2003-07-31 | Shearwater Corp | Water-soluble polymer conjugates of triazine derivatives |
US9926538B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US9926537B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US10160958B2 (en) | 2005-04-11 | 2018-12-25 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US10731139B2 (en) | 2005-04-11 | 2020-08-04 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US11345899B2 (en) | 2005-04-11 | 2022-05-31 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
US11781119B2 (en) | 2005-04-11 | 2023-10-10 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
US10823727B2 (en) | 2009-06-25 | 2020-11-03 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
US11598767B2 (en) | 2009-06-25 | 2023-03-07 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
US11639927B2 (en) | 2009-06-25 | 2023-05-02 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
US11982670B2 (en) | 2009-06-25 | 2024-05-14 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS57192435A (en) | Modified polypeptide | |
MY108496A (en) | Hypoglycemic thiazolidine diones. | |
DE122005000002I1 (en) | Use of venlafaxine or an aryloxy-propanamine derivative for the manufacture of a medicament for the treatment of incontinence. | |
GR1002802B (en) | Cosmetic compositions and skin treatment compositions | |
BG103780A (en) | Antitussive compositions | |
JPS5283846A (en) | Heterocyclic compounds | |
NZ263740A (en) | Ionene polymers as anthelmintics | |
ATE141802T1 (en) | ILLUDIN ANALOGUES USED AS ANTI-TUMOR AGENT | |
MY131053A (en) | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | |
ATE108658T1 (en) | USE OF TETRACYCLINE IN THE MANUFACTURE OF A MEDICATION FOR REDUCING EYE PRESSURE. | |
JPS53130752A (en) | Aqueous silicone emulsion composition | |
JPS56148165A (en) | Brushless motor | |
JPS5626962A (en) | Coating composition | |
MD950010A (en) | Composition for removing or deactivation of toxic components from blood and other extracellular body liquids and methol for prepations theref | |
JPS57165310A (en) | First solution for permanent wave | |
JPS5665825A (en) | Remedy for peptic ulcer | |
NZ217281A (en) | Phenyl ether derivatives and pharmaceutical compositions | |
JPS5526881A (en) | Semisynthesis of insulin | |
IE791946L (en) | Treatment of wood | |
Catsaras | Bacteriological aspect of bovine enterotoxemia. | |
UA28769A (en) | Method of treatment of the skin radiation damages | |
JPS545991A (en) | Thiadiazine derivatives, process for their preparation and their insecticides and miticides | |
JPS5699420A (en) | Immune reactivator | |
JPS53144570A (en) | 1-osoindolinone derivatives and agriculture and horticulture containing the same as active constituents | |
JPS5427590A (en) | Preparation of thiadiazines |